1
|
Ren L, Zhang T, Zhang J. Recent advances in dietary androgen receptor inhibitors. Med Res Rev 2024; 44:1446-1500. [PMID: 38279967 DOI: 10.1002/med.22019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Revised: 12/07/2023] [Accepted: 01/10/2024] [Indexed: 01/29/2024]
Abstract
As a nuclear transcription factor, the androgen receptor (AR) plays a crucial role not only in normal male sexual differentiation and growth of the prostate, but also in benign prostatic hyperplasia, prostatitis, and prostate cancer. Multiple population-based epidemiological studies demonstrated that prostate cancer risk was inversely associated with increased dietary intakes of green tea, soy products, tomato, and so forth. Therefore, this review aimed to summarize the structure and function of AR, and further illustrate the structural basis for antagonistic mechanisms of the currently clinically available antiandrogens. Due to the limitations of these antiandrogens, a series of natural AR inhibitors have been identified from edible plants such as fruits and vegetables, as well as folk medicines, health foods, and nutritional supplements. Hence, this review mainly focused on recent experimental, epidemiological, and clinical studies about natural AR inhibitors, particularly the association between dietary intake of natural antiandrogens and reduced risk of prostatic diseases. Since natural products offer multiple advantages over synthetic antiandrogens, this review may provide a comprehensive and updated overview of dietary-derived AR inhibitors, as well as their potential for the nutritional intervention against prostatic disorders.
Collapse
Affiliation(s)
- Li Ren
- College of Food Science and Engineering, Jilin University, Changchun, China
| | - Tiehua Zhang
- College of Food Science and Engineering, Jilin University, Changchun, China
| | - Jie Zhang
- College of Food Science and Engineering, Jilin University, Changchun, China
| |
Collapse
|
2
|
Doamekpor SK, Peng P, Xu R, Ma L, Tong Y, Tong L. A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations. Acta Crystallogr F Struct Biol Commun 2023; 79:95-104. [PMID: 36995121 PMCID: PMC10071832 DOI: 10.1107/s2053230x23002224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Accepted: 03/07/2023] [Indexed: 03/31/2023] Open
Abstract
Mutations in the androgen receptor (AR) ligand-binding domain (LBD) can cause resistance to drugs used to treat prostate cancer. Commonly found mutations include L702H, W742C, H875Y, F877L and T878A, while the F877L mutation can convert second-generation antagonists such as enzalutamide and apalutamide into agonists. However, pruxelutamide, another second-generation AR antagonist, has no agonist activity with the F877L and F877L/T878A mutants and instead maintains its inhibitory activity against them. Here, it is shown that the quadruple mutation L702H/H875Y/F877L/T878A increases the soluble expression of AR LBD in complex with pruxelutamide in Escherichia coli. The crystal structure of the quadruple mutant in complex with the agonist dihydrotestosterone (DHT) reveals a partially open conformation of the AR LBD due to conformational changes in the loop connecting helices H11 and H12 (the H11-H12 loop) and Leu881. This partially open conformation creates a larger ligand-binding site for AR. Additional structural studies suggest that both the L702H and F877L mutations are important for conformational changes. This structural variability in the AR LBD could affect ligand binding as well as the resistance to antagonists.
Collapse
Affiliation(s)
- Selom K. Doamekpor
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| | - Panfeng Peng
- Suzhou Kintor Pharmaceuticals Inc, No. 20 Songbei Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, People’s Republic of China
| | - Ruo Xu
- Suzhou Kintor Pharmaceuticals Inc, No. 20 Songbei Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, People’s Republic of China
| | - Liandong Ma
- Suzhou Kintor Pharmaceuticals Inc, No. 20 Songbei Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, People’s Republic of China
| | - Youzhi Tong
- Suzhou Kintor Pharmaceuticals Inc, No. 20 Songbei Road, Suzhou Industrial Park, Suzhou, Jiangsu 215123, People’s Republic of China
| | - Liang Tong
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| |
Collapse
|
3
|
Karatt TK, Sathiq MA, Laya S, Philip M, Karakka Kal AK, Subhahar MB. Investigation of in vitro generated metabolites of GLPG0492 using equine liver microsomes for doping control. Drug Test Anal 2023. [PMID: 36762383 DOI: 10.1002/dta.3453] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 01/12/2023] [Accepted: 01/27/2023] [Indexed: 02/11/2023]
Abstract
An effective alternative to testosterone therapy is selective androgen receptor modulators, a class of compounds that has a tissue-specific effect on muscle and bone. These drugs, which enhance performance, pose a severe abuse risk in competitive sports. GLPG0492 is one of the selective androgen receptor modulators discovered in recent decades. This compound has a unique tissue-specific action for muscle and bone against steroid receptors and acts as a partial agonist for androgen receptors. This study examined GLPG0492 and its metabolites in vitro using equine liver microsomes. Liquid chromatography-high-resolution mass spectrometry was utilized to determine the probable structures of detected metabolites. This study identified 39 metabolites of GLPG0492 (21 phase I and 18 phase II). The hydroxylation of GLPG0492 results in monohydroxylated and dihydroxylated metabolites. Additionally, the study detected dissociated side chains (3-methyl and 4-(hydroxymethyl)) and corresponding hydroxylated metabolites. A series of glucuronic acid- and sulfonic acid-conjugated analogs of GLPG0492 were detected during phase II of the study. The findings might help in the detection of GLPG0492 and the elucidation of its illegal use in equestrian sports.
Collapse
Affiliation(s)
- Tajudheen K Karatt
- Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates.,Post Graduate and Research Department of Chemistry, Jamal Mohamed College (Affiliated to Bharathidasan University), Tamil Nadu, India
| | - M Anwar Sathiq
- Post Graduate and Research Department of Chemistry, Jamal Mohamed College (Affiliated to Bharathidasan University), Tamil Nadu, India
| | - Saraswathy Laya
- Department of Chemistry, College of Science, United Arab Emirates University, Al Ain, United Arab Emirates
| | - Moses Philip
- Equine Forensic Unit, Central Veterinary Research Laboratory, Dubai, United Arab Emirates
| | | | | |
Collapse
|
4
|
Radaeva M, Li H, LeBlanc E, Dalal K, Ban F, Ciesielski F, Chow B, Morin H, Awrey S, Singh K, Rennie PS, Lallous N, Cherkasov A. Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors. Cells 2022; 11:cells11182785. [PMID: 36139361 PMCID: PMC9497135 DOI: 10.3390/cells11182785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2022] [Revised: 08/31/2022] [Accepted: 09/02/2022] [Indexed: 11/16/2022] Open
Abstract
The mutation-driven transformation of clinical anti-androgen drugs into agonists of the human androgen receptor (AR) represents a major challenge for the treatment of prostate cancer patients. To address this challenge, we have developed a novel class of inhibitors targeting the DNA-binding domain (DBD) of the receptor, which is distanced from the androgen binding site (ABS) targeted by all conventional anti-AR drugs and prone to resistant mutations. While many members of the developed 4-(4-phenylthiazol-2-yl)morpholine series of AR-DBD inhibitors demonstrated the effective suppression of wild-type AR, a few represented by 4-(4-(3-fluoro-2-methoxyphenyl)thiazol-2-yl)morpholine (VPC14368) exhibited a partial agonistic effect toward the mutated T878A form of the receptor, implying their cross-interaction with the AR ABS. To study the molecular basis of the observed cross-reactivity, we co-crystallized the T878A mutated form of the AR ligand binding domain (LBD) with a bound VPC14368 molecule. Computational modelling revealed that helix 12 of AR undergoes a characteristic shift upon VPC14368 binding causing the agonistic behaviour. Based on the obtained structural data we then designed derivatives of VPC14368 to successfully eliminate the cross-reactivity towards the AR ABS, while maintaining significant anti-AR DBD potency.
Collapse
Affiliation(s)
- Mariia Radaeva
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Huifang Li
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Eric LeBlanc
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Kush Dalal
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Fuqiang Ban
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | | | - Bonny Chow
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Helene Morin
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Shannon Awrey
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Kriti Singh
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Paul S. Rennie
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
| | - Nada Lallous
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
- Correspondence: (N.L.); (A.C.)
| | - Artem Cherkasov
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada
- Correspondence: (N.L.); (A.C.)
| |
Collapse
|
5
|
Sreelakshmi P, Krishna BS, Santhisudha S, Murali S, Reddy GR, Venkataramaiah C, Rao PV, Reddy AVK, Swetha V, Zyryanov GV, Reddy CD, Reddy CS. Synthesis and biological evaluation of novel dialkyl (4-amino-5H-chromeno[2,3-d]pyrimidin-5-yl)phosphonates. Bioorg Chem 2022; 129:106121. [PMID: 36075177 DOI: 10.1016/j.bioorg.2022.106121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2022] [Revised: 08/28/2022] [Accepted: 08/29/2022] [Indexed: 11/02/2022]
Abstract
This study reports the design and synthesis of novel dialkyl (4-amino-5H-chromeno[2,3-d]pyrimidin-5-yl)phosphonates as potential antitumor agents against A549 (lung cancer), DU-145 (prostate cancer), PC-3 (prostate cancer), HeLa (cervical cancer) and MCF-7 (breast cancer), cell lines evidenced from the in vitro antitumor studies performed by MTT assay (across 10-30 μM concentrations). The structural eminence of these synthesized molecules has emanated by designing the structural core by uniting the chromene, pyrimidine and phosphonate moieties into one, which has augmented their novelty and made them unreported. Further the deep structural activity relationship study investigations articulated that the title compounds are promising drug-like compounds and potential inhibitor of histidine amino acid residue present on the respective enzymatic proteins [3QJZ (A549), 3VHE (DU-145), 3V49 (PC-3), 3F81 (HeLa), & 3R7Q (MCF-7)] of the cell lines screened and are identified as responsible for the multi-faceted antitumor activities predicted in vitro. The obtained results were further supported by molecular docking studies, QSAR, ADMET, and bioactivity studies which have supported them as potential BBB penetrable molecules and proficient CNS active neuro-protective agents during drug delivery.
Collapse
Affiliation(s)
- Poola Sreelakshmi
- Department of Chemistry, Sri Venkateswara University, Tirupati 517 502, India
| | | | - Sarva Santhisudha
- Department of Chemistry, Sri Venkateswara University, Tirupati 517 502, India
| | - Sudileti Murali
- Department of Chemistry, Sri Venkateswara University, Tirupati 517 502, India
| | | | - Chintha Venkataramaiah
- Department of Zoology, Sri Venkateswara University, Tirupati 517 502, India; Department of Medical Environmental Biology and Tropical Medicine, School of Medicine, Kangwon National University, Chuncheon, Gangwon-Do 24341, Republic of Korea
| | - Pasupuleti Visweswara Rao
- Centre for International Collaboration and Research, Reva University, Rukmini Knowledge Park, Bangalore 560 064, India; Department of Biochemistry, Faculty of Medicine and Health Sciences, Abdurrab University, Jl Riau Ujung No. 73, Pekanbaru 28292, Riau, Indonesia.
| | - Avula Vijaya Kumar Reddy
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg 620002, Russian Federation
| | - Vallela Swetha
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg 620002, Russian Federation
| | - Grigory Vasilievich Zyryanov
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg 620002, Russian Federation; Ural Division of the Russian Academy of Sciences, I. Ya. Postovskiy Institute of Organic Synthesis, 22 S., Kovalevskoy Street, Yekaterinburg 620219, Russian Federation
| | | | | |
Collapse
|
6
|
Abstract
The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.
Collapse
Affiliation(s)
- Weiguo Xiang
- Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| | - Shaomeng Wang
- Departments of Internal Medicine, Pharmacology and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
7
|
Wen J, Feng L, Zhao H, Zheng L, Stavropoulos P, Ai L, Zhang J. Chiral Recognition of Hydantoin Derivatives Enabled by Tetraaza Macrocyclic Chiral Solvating Agents Using 1H NMR Spectroscopy. J Org Chem 2022; 87:7934-7944. [PMID: 35675642 DOI: 10.1021/acs.joc.2c00587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Enantiomers of a series of hydantoin derivatives were prepared from d- and l-amino acids with p-tolyl isocyanate and 3,5-bis(trifluoromethyl)phenyl isocyanate as guests for chiral recognition by 1H NMR spectroscopy. Meanwhile, several tetraaza macrocyclic compounds were synthesized as chiral solvating agents from d-phenylalanine and (1S,2S)-(+)-1,2-diaminocyclohexane. An uncommon enantiomeric discrimination has been successfully established for hydantoin derivatives, representatives of five-membered N,N-heterocycles, in the presence of tetraaza macrocyclic chiral solvating agents (TAMCSAs) 1a-1c by means of 1H NMR spectroscopy. Several unprecedented nonequivalent chemical shifts (up to 1.309 ppm) were observed in the split 1H NMR spectra. To evaluate practical applications in the determination of enantiomeric excess (ee), the ee values of samples with different optical purities (up to 95% ee) were accurately calculated by the integration of relevant proton peaks. To better understand the chiral discriminating behavior, Job plots of (±)-G1 with TAMCSA 1a were investigated. Furthermore, in order to further explore any underlying intermolecular hydrogen bonding interactions, theoretical calculations of the enantiomers of (S)-G1 and (R)-G1 with TAMCSA 1a were performed by means of the hybrid density functional theory (B3LYP/6-31G*) of the Gaussian 16 program.
Collapse
Affiliation(s)
- Jie Wen
- College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China
| | - Lei Feng
- College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China
| | - Hongmei Zhao
- State Key Laboratory of Information Photonics and Communications, School of Science, Beijing University of Posts and Telecommunications, Beijing 100876, P. R. China
| | - Li Zheng
- College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China
| | - Pericles Stavropoulos
- Department of Chemistry, Missouri University of Science and Technology, Rolla, Missouri 65409, United States
| | - Lin Ai
- College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China
| | - Jiaxin Zhang
- College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China
| |
Collapse
|
8
|
Bhogireddy DN, Surapureddi SR, Syed T, Prashanth T, Tadiboina BR. Synthesis and biological evaluation of aryl derivatives of isoxazole pyrazolo[1,5-a] pyrimidines as anticancer agents. SYNTHETIC COMMUN 2022. [DOI: 10.1080/00397911.2022.2056846] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Danayya Nayudu Bhogireddy
- Department of Chemistry, KoneruLakshmaiah Education Foundation, Vaddeswaram, Guntur, India
- Laurus Labs Limited, IKP Knowledge Park, Genome Valley, Hyderabad, Telangana, India
| | | | - Tasqeeruddin Syed
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Thodupunuri Prashanth
- Organic and Biomolecular Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, India
| | - Bhaskara Rao Tadiboina
- Department of Chemistry, KoneruLakshmaiah Education Foundation, Vaddeswaram, Guntur, India
| |
Collapse
|
9
|
Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998–2021). Eur J Med Chem 2022; 230:114119. [DOI: 10.1016/j.ejmech.2022.114119] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 12/20/2021] [Accepted: 01/09/2022] [Indexed: 02/08/2023]
|
10
|
Fu C, Xiong Q, Xiao L, He L, Bai T, Zhang Z, Dong X, Wang C. Stereodivergent Synthesis of Carbocyclic Quaternary
α‐Amino
Acid Derivatives Containing Two Contiguous Stereocenters. CHINESE J CHEM 2022. [DOI: 10.1002/cjoc.202100824] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Cong Fu
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
| | - Qi Xiong
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
| | - Lu Xiao
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
- State Key Laboratory of Organometallic Chemistry Shanghai Institute of Organic Chemistry Shanghai 230021 China
| | - Ling He
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
| | - Tian Bai
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
| | - Zongpeng Zhang
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
| | - Xiu‐Qin Dong
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
- Suzhou Institute of Wuhan University Suzhou Jiangsu 215123 P. R. China
| | - Chun‐Jiang Wang
- Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences Wuhan University Wuhan 430072 China
- State Key Laboratory of Organometallic Chemistry Shanghai Institute of Organic Chemistry Shanghai 230021 China
| |
Collapse
|
11
|
Zhang MC, Wang DC, Qu GR, Guo HM. Catalytic Asymmetric Synthesis of Chiral Thiohydantoins via Domino Cyclization Reaction of β,γ-Unsaturated α-Ketoester and N,N'-Dialkylthiourea. Org Chem Front 2022. [DOI: 10.1039/d2qo00669c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The first catalytic asymmetric route to synthesize chiral thiohydantoins containing a quaternary stereogenic center has been established utilizing a chiral phosphoric acid-catalyzed domino cyclization reaction of N,N'-dialkyl thioureas with β,γ-unsaturated...
Collapse
|
12
|
Conformational dynamics of androgen receptors bound to agonists and antagonists. Sci Rep 2021; 11:15887. [PMID: 34354111 PMCID: PMC8342701 DOI: 10.1038/s41598-021-94707-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2021] [Accepted: 07/13/2021] [Indexed: 11/09/2022] Open
Abstract
The androgen receptor (AR) is critical in the progression of prostate cancer (PCa). Small molecule antagonists that bind to the ligand binding domain (LBD) of the AR have been successful in treating PCa. However, the structural basis by which the AR antagonists manifest their therapeutic efficacy remains unclear, due to the lack of detailed structural information of the AR bound to the antagonists. We have performed accelerated molecular dynamics (aMD) simulations of LBDs bound to a set of ligands including a natural substrate (dihydrotestosterone), an agonist (RU59063) and three antagonists (bicalutamide, enzalutamide and apalutamide) as well as in the absence of ligand (apo). We show that the binding of AR antagonists at the substrate binding pocket alter the dynamic fluctuations of H12, thereby disrupting the structural integrity of the agonistic conformation of AR. Two antagonists, enzalutamide and apalutamide, induce considerable structural changes to the agonist conformation of LBD, when bound close to H12 of AR LBD. When the antagonists bind to the pocket with different orientations having close contact with H11, no significant conformational changes were observed, suggesting the AR remains in the functionally activated (agonistic) state. The simulations on a drug resistance mutant F876L bound to enzalutamide demonstrated that the mutation stabilizes the agonistic conformation of AR LBD, which compromises the efficacy of the antagonists. Principal component analysis (PCA) of the structural fluctuations shows that the binding of enzalutamide and apalutamide induce conformational fluctuations in the AR, which are markedly different from those caused by the agonist as well as another antagonist, bicalutamide. These fluctuations could only be observed with the use of aMD.
Collapse
|
13
|
Syed T, Asiri YI, Shaheen S, Gangarapu K. Design, synthesis and anticancer evaluation of structurally modified substituted aryl-quinazoline derivatives as anticancer agents. SYNTHETIC COMMUN 2021. [DOI: 10.1080/00397911.2021.1941113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- Tasqeeruddin Syed
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Yahya I. Asiri
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia
| | - Shaheen Shaheen
- Anwarul Uloom College of Pharmacy, Mallepally, Hyderabad, India
| | - Kiran Gangarapu
- School of Pharmacy, Anurag Group of Institutions, Hyderabad, India
| |
Collapse
|
14
|
Bhole RP, Chikhale RV, Wavhale RD, Asmary FA, Almutairi TM, Alhajri HM, Bonde CG. Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents. Heliyon 2021; 7:e06227. [PMID: 33869816 PMCID: PMC8035491 DOI: 10.1016/j.heliyon.2021.e06227] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2020] [Revised: 01/13/2021] [Accepted: 02/04/2021] [Indexed: 01/20/2023] Open
Abstract
The androgen receptor inhibitor, Enzalutamide, proved effective against castration resistance prostate cancer, has demonstrated clinical benefits and increased survival rate in men. However, AR mutation (F876L) converts Enzalutamide from antagonist to agonist indicating a rapid evolution of resistance. Hence, our goal is to overcome this resistance mechanism by designing and developing novel Enzalutamide analogues. We designed a dataset of Enzalutamide derivatives using Enzalutamide's shape and electrostatic features to match with pharmacophoric features essential for tight binding with the androgen receptor. Based on this design strategy ten novel derivatives were selected including 5,5-dimethyl-3-(6-substituted benzo[d]thia/oxazol-2-yl)-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl)imidazolidin-4-one (6a-j) for synthesis. All the compounds were evaluated in-vitro on prostate cancer cell lines DU-145, LNCaP and PC3. Interestingly, two compounds 3-(6-hydroxybenzo[d]thiazol-2-yl)-5,5-dimethyl-2-thioxo-1-(4-(trifluoromethyl)pyridin-2-yl) imidazolidin-4-one (6c, IC50 - 18.26 to 20.31μM) and 3-(6-hydroxybenzo[d]oxazol-2-yl)-5,5-dimethyl -2-thioxo- 1- (4-(trifluoromethyl) pyridin-2-yl)imidazolidin-4-one (6h, IC50 - 18.26 to 20.31μM) were successful with promising in-vitro antiproliferative activity against prostate cancer cell lines. The binding mechanism of potential androgen receptor inhibitors was further studied by molecular docking, molecular dynamics simulations and MM-GBSA binding free energy calculations and found in agreement with the in vitro studies. It provided strong theoretical support to our hypothesis.
Collapse
Affiliation(s)
- Ritesh P. Bhole
- Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, Maharashtra, India
| | - Rupesh V. Chikhale
- Division of Pharmacy and Optometry, University of Manchester, Manchester, UK
- School of Pharmacy, University of East Anglia, Norwich, UK
| | - Ravindra D. Wavhale
- Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune 411018, Maharashtra, India
| | - Fatmah Ali Asmary
- Department of Chemistry, P.O. Box 2455, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Tahani Mazyad Almutairi
- Department of Chemistry, P.O. Box 2455, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Hassna Mohammed Alhajri
- Department of Chemistry, P.O. Box 2455, College of Science, King Saud University, Riyadh, 11451, Saudi Arabia
| | - Chandrakant G. Bonde
- School of Pharmacy & Technology Management, SVKM's NarseeMonjee Institute of Management & Studies (NMIMS), Mukesh Patel Technology Park, Shirpur, Dhule, 425405, Maharashtra, India
| |
Collapse
|
15
|
Scott DE, Rooney TPC, Bayle ED, Mirza T, Willems HMG, Clarke JH, Andrews SP, Skidmore J. Systematic Investigation of the Permeability of Androgen Receptor PROTACs. ACS Med Chem Lett 2020; 11:1539-1547. [PMID: 32832021 DOI: 10.1021/acsmedchemlett.0c00194] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/01/2020] [Indexed: 02/07/2023] Open
Abstract
Bifunctional molecules known as PROTACs simultaneously bind an E3 ligase and a protein of interest to direct ubiquitination and clearance of that protein, and they have emerged in the past decade as an exciting new paradigm in drug discovery. In order to investigate the permeability and properties of these large molecules, we synthesized two panels of PROTAC molecules, constructed from a range of protein-target ligands, linkers, and E3 ligase ligands. The androgen receptor, which is a well-studied protein in the PROTAC field was used as a model system. The physicochemical properties and permeability of PROTACs are discussed.
Collapse
Affiliation(s)
- Duncan E. Scott
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - Timothy P. C. Rooney
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - Elliott D. Bayle
- Alzheimer’s Research UK UCL Drug Discovery Institute, The Cruciform Building, University College London, Gower Street, London WC1E 6BT, United Kingdom
- The Francis Crick Institute, 1 Midland Road, Kings Cross, London NW1 1AT, United Kingdom
| | - Tashfina Mirza
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - Henriette M. G. Willems
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - Jonathan H. Clarke
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - Stephen P. Andrews
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| | - John Skidmore
- ALBORADA Drug Discovery Institute, University of Cambridge, Island Research Building, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0AH, United Kingdom
| |
Collapse
|
16
|
Yu J, Zhou P, Du W, Xu R, Yan G, Deng Y, Li X, Chen Y. Metabolically stable diphenylamine derivatives suppress androgen receptor and BET protein in prostate cancer. Biochem Pharmacol 2020; 177:113946. [PMID: 32247852 DOI: 10.1016/j.bcp.2020.113946] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 03/31/2020] [Indexed: 02/05/2023]
Abstract
Androgen receptor (AR) is a crucial driver of prostate cancer (PC). AR-relevant resistance remains a major challenge in castration-resistant prostate cancer (CRPC). Bromodomain and extra-terminal domain (BET) family are critical AR coregulators. Here, we developed several diphenylamine derivatives and identified compound 7d that disrupted the functions of AR and BET family in prostate cancer and exhibited favorable metabolic stability in vitro and high drug exposure in vivo. We showed 7d not only bound to AR, suppressed transactivation of wild-type AR (wt-AR) and the mutant that mediates Enzalutamide resistance, but also reduced c-Myc protein expression through BET inhibition. In addition, 7d inhibited the proliferation of AR-positive PC cells with favorable selectivity and suppressed AR-V7-expressing VCaP and 22Rv1 xenografts growth in vivo. Collectively, these results indicate the potential of lead compound 7d as an orally available AR and BET inhibitor to treat CRPC and overcome antiandrogen resistance.
Collapse
Affiliation(s)
- Jiang Yu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Peiting Zhou
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Wu Du
- Hinova Pharmaceuticals Inc., 4th Floor, Building RongYao A, No. 5, Keyuan South Road, Chengdu 610041, China
| | - Ruixue Xu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Guoyi Yan
- Department of Hepatobiliary Pancreatic Surgery, Henan Province People's Hospital, Zhengzhou 450003, China
| | - Yufang Deng
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China
| | - Xinghai Li
- Hinova Pharmaceuticals Inc., 4th Floor, Building RongYao A, No. 5, Keyuan South Road, Chengdu 610041, China
| | - Yuanwei Chen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China; Hinova Pharmaceuticals Inc., 4th Floor, Building RongYao A, No. 5, Keyuan South Road, Chengdu 610041, China.
| |
Collapse
|
17
|
López-López LI, de Loera D, Rivera-Avalos E, Sáenz-Galindo A. Green Synthesis of Hydantoins and Derivatives. MINI-REV ORG CHEM 2020. [DOI: 10.2174/1570193x16666181206100225] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The hydantoin moiety is found in several bioactive compounds with important pharmacological properties such as antimicrobial, antifungal, anti-androgens, anticancer and the historical action anticonvulsant. Because of these reasons, the synthesis of these compounds and their derivatives is important to review considering the philosophy of the green chemistry. In this review, we present the actual importance in the green synthesis of hydantoins and their derivatives using green methods, such as microwave and ultrasound irradiation, ionic liquids, solid-phase and solvent-free synthesis. Finally, several green protocols reported have been discussed.
Collapse
Affiliation(s)
| | - Denisse de Loera
- School of Chemistry, Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico
| | - Ernesto Rivera-Avalos
- School of Chemistry, Universidad Autonoma de San Luis Potosi, San Luis Potosi, Mexico
| | | |
Collapse
|
18
|
Ananth AH, Manikandan N, Rajan RK, Elancheran R, Lakshmithendral K, Ramanathan M, Bhattacharjee A, Kabilan S. Design, Synthesis, and Biological Evaluation of 2-(2-Bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole Derivatives as Possible Anti-Breast Cancer Agents. Chem Biodivers 2020; 17:e1900659. [PMID: 31995280 DOI: 10.1002/cbdv.201900659] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Accepted: 01/07/2020] [Indexed: 12/19/2022]
Abstract
Breast Cancer (BCa) is the most often diagnosed cancer among women who were in the late 1940's. Breast cancer growth is largely dependent on the expression of estrogen and progesterone receptor. Breast cancer cells may have one, both, or none of these receptors. The treatment for breast cancer may involve surgery, hormonal therapy (Tamoxifen, an aromatase inhibitor, etc.) and oral chemotherapeutic drugs. The molecular docking technique reported the findings on the potential binding modes of the 2-(2-bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole derivatives with the estrogen receptor (PDB ID: 3ERT). The 1,3,4-oxadiazole derivatives 4a-4j have been synthesized and described by spectroscopic method. 2-(2-Bromo-6-nitrophenyl)-5-(4-bromophenyl)-1,3,4-oxadiazole (4c) was reconfirmed by single-crystal XRD. All the compounds have been tested in combination with generic Imatinib pharmaceutical drug against breast cancer cell lines isolated from Caucasian woman MCF-7, MDA-MB-453 and MCF-10A non-cancer cell lines. The compounds with the methoxy (in 4c) and methyl (in 4j) substitution were shown to have significant cytotoxicity, with 4c showing dose-dependent activation and decreased cell viability. The mechanism of action was reported by induced apoptosis and tested by a DNA enzyme inhibitor experiment (ELISA) for Methyl Transferase. Molecular dynamics simulations were made for hit molecule 4c to study the stability and interaction of the protein-ligand complex. The toxicity properties of ADME were calculated for all the compounds. All these results provide essential information for further clinical trials.
Collapse
Affiliation(s)
- Arjun H Ananth
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, 608002, Tamil Nadu, India
| | - Natarajan Manikandan
- Department of Pharmacology, PSG College of Pharmacy, Coimbatore, 641004, Tamil Nadu, India
| | - Ravi Kumar Rajan
- Department of Pharmacology, PSG College of Pharmacy, Coimbatore, 641004, Tamil Nadu, India
| | - Ramakrishnan Elancheran
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, 608002, Tamil Nadu, India
| | | | - Muthiah Ramanathan
- Department of Pharmacology, PSG College of Pharmacy, Coimbatore, 641004, Tamil Nadu, India
| | - Atanu Bhattacharjee
- Computational Biology Laboratory, Department of Biotechnology and Bioinformatics, North-Eastern Hill University, Shillong, 793022, India
| | - Senthamaraikannan Kabilan
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, 608002, Tamil Nadu, India
| |
Collapse
|
19
|
Kotha S, Gupta NK, Aswar VR. Multicomponent Approach to Hydantoins and Thiohydantoins Involving a Deep Eutectic Solvent. Chem Asian J 2019; 14:3188-3197. [DOI: 10.1002/asia.201900744] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 07/31/2019] [Indexed: 12/15/2022]
Affiliation(s)
- Sambasivarao Kotha
- Department of ChemistryIndian Institute of Technology Bombay Powai Mumbai 400 076 India
| | - Naveen K. Gupta
- Department of ChemistryIndian Institute of Technology Bombay Powai Mumbai 400 076 India
| | - Vikas R. Aswar
- Department of ChemistryIndian Institute of Technology Bombay Powai Mumbai 400 076 India
| |
Collapse
|
20
|
Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants. Eur J Med Chem 2019; 182:111608. [PMID: 31437779 DOI: 10.1016/j.ejmech.2019.111608] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 07/26/2019] [Accepted: 08/07/2019] [Indexed: 02/05/2023]
Abstract
Androgen receptor (AR) has been a target of prostate cancer (PC) for nearly six decades. Recently, downregulating or degrading AR and the mutants especially the splice variant 7 (AR-V7) lacking ligand binding domain (LBD) emerged as an advantageous therapeutic approach to overcome drug resistance. Here, the structural modification of darolutamide resulted in the discovery of dual-action AR inhibitors and down-regulators. Unlike other traditional AR antagonists targeting the AR-LBD, compounds 4k and 4b not only inhibit the activities of wt-AR and AR-F876L mutant but also downregulate the protein expression of full-length (AR-full) and AR variant 7 (AR-V7) at mRNA level. In cell proliferation assays, compounds 4k and 4b exhibited better antiproliferative activities than darolutamide and enzalutamide against AR-V7-positive 22Rv1 cells and VCaP cells. In addition, 4k demonstrated better antitumor activity than clinically used enzalutamide in castration-resistant VCaP xenograft model. Collectively, combining the activities of AR inhibition and downregulation, compound 4k is proposed as an advantageous lead compound to disrupt AR signaling and overcome resistance.
Collapse
|
21
|
Arjun HA, Elancheran R, Manikandan N, Lakshmithendral K, Ramanathan M, Bhattacharjee A, Lokanath NK, Kabilan S. Design, Synthesis, and Biological Evaluation of (E)-N'-((1-Chloro-3,4-Dihydronaphthalen-2-yl)Methylene)Benzohydrazide Derivatives as Anti-prostate Cancer Agents. Front Chem 2019; 7:474. [PMID: 31355179 PMCID: PMC6636335 DOI: 10.3389/fchem.2019.00474] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Accepted: 06/20/2019] [Indexed: 01/09/2023] Open
Abstract
Prostate Cancer (PCa) is the most frequently diagnosed cancer in men in their late '50s. PCa growth is mainly due to the activation of the androgen receptor by androgens. The treatment for PCa may involve surgery, hormonal therapy, and oral chemotherapeutic drugs. A structural based molecular docking approach revealed the findings of (E)-N'-((1-chloro-3,4-dihydronaphthalen-2-yl)methylene)benzohydrazide derivatives, where the possible binding modes of the compounds with protein (PDB ID: 3V49) are shown. The compounds (6a-k) were synthesized and characterized by using conventional methods. The compounds, 6g, 6j, and 6k were reconfirmed through single crystal X-ray diffraction (XRD). Further, the compounds (6a-k) and standard drug were evaluated against human prostate cancer cell lines, LNCaP and PC-3 and the non-cancerous cell line, 3T3. Among these compounds, 6g and 6j showed higher cytotoxicity, and 6g exhibited dose-dependent activity and reduced cell viability. The mechanism of action was observed through the induced apoptosis and was further confirmed by western blot and ELISA. Molecular dynamics simulation studies were carried out to calculate the interaction and the stability of the protein-ligand complex in motion. ADME properties were predicted for all the tested compounds. These findings may give vital information for further development.
Collapse
Affiliation(s)
- H. A. Arjun
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, India
| | | | - N. Manikandan
- Department of Pharmacology, PSG College of Pharmacy, Coimbatore, India
| | - K. Lakshmithendral
- Drug Discovery Lab, Department of Chemistry, Annamalai University, Chidambaram, India
| | | | - Atanu Bhattacharjee
- Computational Biology Laboratory, Department of Biotechnology & Bioinformatics, North Eastern Hill University, Shillong, India
| | - N. K. Lokanath
- Department of Physics, University of Mysore, Mysore, India
| | | |
Collapse
|
22
|
LEE YK, CHANG YH. Physicochemical and antioxidant properties of methanol extract from Maca (Lepidium meyenii Walp.) leaves and roots. FOOD SCIENCE AND TECHNOLOGY 2019. [DOI: 10.1590/fst.03818] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
23
|
Yu J, Zhang L, Yan G, Zhou P, Cao C, Zhou F, Li X, Chen Y. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer. Eur J Med Chem 2019; 171:265-281. [PMID: 30925341 DOI: 10.1016/j.ejmech.2019.03.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2018] [Revised: 03/14/2019] [Accepted: 03/16/2019] [Indexed: 02/05/2023]
Abstract
Prostate cancer (PC) is the second most common malignancy in men worldwide. Among current therapies, two antiandrogens, Abiraterone Acetate and Enzalutamide (Enza) have become the standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we designed and synthesized a new series of nonsteroidal compounds deriving from the hybridization of Abiraterone (Abi) and Enzalutamide, among which compound 4a featuring the diphenylamine scaffold was identified as a potent and cell selective androgen receptor (AR) antagonist. In cell proliferation assays, compound 4a exhibited better antiproliferative activities than Enzalutamide against AR-overexpressing VCaP cells and 22Rv1 cells bearing H874Y-mutated AR. In addition, 4a suppressed the activity of AR-F876L mutant that confers resistance to Enzalutamide and efficiently blocked R1881-induced PSA and FKBP5 gene expression. In competitive binding assay, compound 4a displayed higher binding affinity to AR than Enzalutamide. These results suggest compound 4a as a potential candidate to treat Enza-resistant CRPC.
Collapse
Affiliation(s)
- Jiang Yu
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
| | - Lanxi Zhang
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
| | - Guoyi Yan
- Department of Hepatobiliary Pancreatic Surgery, Henan Province People's Hospital, Zhengzhou, 450003, China
| | - Peiting Zhou
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
| | - Chaoguo Cao
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
| | - Fei Zhou
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China
| | - Xinghai Li
- Hinova Pharmaceuticals Inc, 4th Floor, Building RongYao A, No. 5, Keyuan South Road, Chengdu, 610041, China
| | - Yuanwei Chen
- State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, China; Hinova Pharmaceuticals Inc, 4th Floor, Building RongYao A, No. 5, Keyuan South Road, Chengdu, 610041, China.
| |
Collapse
|
24
|
Bolla RS, Gandikota NM, Kasi Viswanath IV. Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin. Curr Radiopharm 2019; 12:82-87. [PMID: 30854946 DOI: 10.2174/1874471012666181130162731] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2018] [Revised: 10/25/2018] [Accepted: 11/05/2018] [Indexed: 11/22/2022]
Abstract
OBJECTIVE Stable and non-radioactive isotope labeled compounds gained significance in recent drug discovery and other various applications such as bio-analytical studies. The modern bioanalytical techniques can study the adverse therapeutic effects of drugs by comparing isotopically labeled internal standards. A well-designed labeled compound can provide high-quality information about the identity and quantification of drug-related compounds in biological samples. This information can be very useful at key decision points in drug development. In this study, we tried to synthesize Nilutamide- d6 which can be useful to study the adverse effects of Nilutamide, and based on these can modify or widen the new drug derivatives. Nilutamide is a nonsteroidal antiandrogen which is used in the treatment of prostate cancer. The aim of this study was to develop a synthetic approach to prepare deuterium labeled [2H6]-5, 5-dimethylimidazolidine-2, 4-dione and [2H6]-nilutamide. METHODS Since nilutamide is a derivative of hydantoin, it involves the synthesis of Dimethylhydantoin via Bucherer-Bergs hydantoin synthesis, followed by oxidative N-arylation with 4-iodo-1-nitro-2- (trifluoromethyl) benzene. CONCLUSION We successfully synthesized [2H6]-nilutamide and [2H6]-dimethylhydantoin with good isotopic purity, measured to be of adequate quality for use as internal standards in bio-analytical studies. A brief mechanistic study of Bucherer-Bergs hydantoin reaction was carried and the reason for possible H/D exchange was explained.
Collapse
Affiliation(s)
- Ratna Sekhar Bolla
- Department of Chemistry, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Guntur Dist 522502, India
| | | | | |
Collapse
|
25
|
Recent applications of hydantoin and thiohydantoin in medicinal chemistry. Eur J Med Chem 2019; 164:517-545. [DOI: 10.1016/j.ejmech.2018.12.066] [Citation(s) in RCA: 63] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2018] [Revised: 12/24/2018] [Accepted: 12/25/2018] [Indexed: 12/17/2022]
|
26
|
Liu N, Zhou W, Guo Y, Wang J, Fu W, Sun H, Li D, Duan M, Hou T. Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator. J Chem Inf Model 2018; 58:1652-1661. [PMID: 29993249 DOI: 10.1021/acs.jcim.8b00283] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The androgen receptor (AR) plays important roles in gene expression regulation, sexual phenotype maintenance, and prostate cancer (PCa) development. The communications between the AR ligand-binding domain (LBD) and its coactivator are critical to the activation of AR. It is still unclear how the ligand binding would affect the AR-coactivator interactions. In this work, the effects of the ligand binding on the AR-coactivator communications were explored by molecular dynamics (MD) simulations. The results showed that the ligand binding regulates the residue interactions in the function site AF-2. The ligand-to-coactivator allosteric pathway, which involves the coactivator, helix 3 (H3), helix 4 (H4), the loop between H3 and H4 (L3), and helix 12 (H12), and ligands, was characterized. In addition, the interactions of residues on the function site BF-3, especially on the boundary of AF-2 and BF-3, are also affected by the ligands. The MM/GBSA free energy calculations demonstrated that the binding affinity between the coactivator and apo-AR is roughly weaker than those between the coactivator and antagonistic ARs but stronger than those between the coactivator and agonistic ARs. The results indicated that the long-range electrostatic interactions and the conformational entropies are the main factors affecting the binding free energies. In addition, the F876L mutation on AR-LBD affects the ligand-to-coactivator allosteric pathway, which could be the reason for point mutation induced tolerance for the antagonistic drugs such as enzalutamide. Our study would help to develop novel drug candidates against PCa.
Collapse
Affiliation(s)
- Na Liu
- Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan , Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences , Wuhan 430071 , China.,University of Chinese Academy of Sciences , Beijing 100049 , People's Republic of China
| | - Wenfang Zhou
- College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , Zhejiang 310058 , People's Republic of China
| | - Yue Guo
- Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan , Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences , Wuhan 430071 , China.,University of Chinese Academy of Sciences , Beijing 100049 , People's Republic of China
| | - Junmei Wang
- Department of Pharmaceutical Sciences , University of Pittsburgh , Pittsburgh , Pennsylvania 15261 , United States
| | - Weitao Fu
- College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , Zhejiang 310058 , People's Republic of China
| | - Huiyong Sun
- College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , Zhejiang 310058 , People's Republic of China
| | - Dan Li
- College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , Zhejiang 310058 , People's Republic of China
| | - Mojie Duan
- Key Laboratory of Magnetic Resonance in Biological Systems, State Key Laboratory of Magnetic Resonance and Atomic and Molecular Physics, National Center for Magnetic Resonance in Wuhan , Wuhan Institute of Physics and Mathematics, Chinese Academy of Sciences , Wuhan 430071 , China
| | - Tingjun Hou
- College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , Zhejiang 310058 , People's Republic of China
| |
Collapse
|
27
|
Graham SE, Leja N, Carlson HA. MixMD Probeview: Robust Binding Site Prediction from Cosolvent Simulations. J Chem Inf Model 2018; 58:1426-1433. [PMID: 29905479 DOI: 10.1021/acs.jcim.8b00265] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Mixed-solvent molecular dynamics (MixMD) is a cosolvent simulation technique for identifying binding hotspots and specific favorable interactions on a protein's surface. MixMD studies have the ability to identify these biologically relevant sites by examining the occupancy of the cosolvent over the course of the simulation. However, previous MixMD analysis required a great deal of manual inspection to identify relevant sites. To address this limitation, we have developed MixMD Probeview as a plugin for the freely available, open-source version of the molecular visualization program PyMOL. MixMD Probeview incorporates two analysis procedures: (1) identifying and ranking whole binding sites and (2) identifying and ranking local maxima for each probe type. These functionalities were validated using four common benchmark proteins, including two with both active and allosteric sites. In addition, three different cosolvent procedures were compared to examine the impact of including more than one cosolvent in the simulations. For all systems tested, MixMD Probeview successfully identified known active and allosteric sites based on the total occupancy of neutral probe molecules. As an easy-to-use PyMOL plugin, we expect that MixMD Probeview will facilitate identification and analysis of binding sites from cosolvent simulations performed on a wide range of systems.
Collapse
|
28
|
Thevis M, Schänzer W. Detection of SARMs in doping control analysis. Mol Cell Endocrinol 2018; 464:34-45. [PMID: 28137616 DOI: 10.1016/j.mce.2017.01.040] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/07/2016] [Revised: 01/24/2017] [Accepted: 01/24/2017] [Indexed: 11/27/2022]
Abstract
The class of selective androgen receptor modulators (SARMs) has been the subject of intense and dedicated clinical research over the past two decades. Potential therapeutic applications of SARMs are manifold and focus particularly on the treatment of conditions manifesting in muscle loss such as general sarcopenia, cancer-associated cachexia, muscular dystrophy, etc. Consequently, based on the substantial muscle- and bone-anabolic properties of SARMs, these agents constitute substances with significant potential for misuse in sport and have therefore been added to the Word Anti-Doping Agency's (WADA's) Prohibited List in 2008. Since then, numerous adverse analytical findings have been reported for various different SARMs, which has underlined the importance of proactive and preventive anti-doping measures concerning emerging drugs such as these anabolic agents, which have evidently been misused in sport despite the fact that none of these SARMs has yet received full clinical approval. In this review, analytical data on SARMs generated in the context of research conducted for sports drug testing purposes are summarized and state-of-the-art test methods aiming at intact drugs as well as diagnostic urinary metabolites are discussed. Doping control analytical approaches predominantly rely on chromatography hyphenated to mass spectrometry, which have allowed for appropriately covering the considerable variety of pharmacophores present in SARMs such as the non-steroidal representatives ACP-105, BMS-564929, GLPG0492 (DT-200), LG-121071, LGD-2226, LGD-4033/VK 5211, ostarine/enobosarm, RAD-140, S-40503, etc. as well as steroidal compounds such as MK-0773 and YK-11.
Collapse
Affiliation(s)
- Mario Thevis
- German Sport University Cologne, Center for Preventive Doping Research/Institute of Biochemistry, Am Sportpark Muengersdorf 6, 50933 Cologne, Germany; European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
| | - Wilhelm Schänzer
- German Sport University Cologne, Center for Preventive Doping Research/Institute of Biochemistry, Am Sportpark Muengersdorf 6, 50933 Cologne, Germany
| |
Collapse
|
29
|
Monteiro JL, Moreira NM, dos Santos DA, Paixão MW, Corrêa AG. Step economy strategy for the synthesis of amphoteric aminoaldehydes, key intermediates for reduced hydantoins. PURE APPL CHEM 2018. [DOI: 10.1515/pac-2017-0705] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Despite of the orthogonal reactivity of the N–H aziridines aldehyde, these compounds exist as an equilibrium of three different forms – whereas the dimeric one is mostly observed in a variety of solvents. In this work, we have developed an alternative protocol for the aminoaldehyde dimers synthesis in two steps starting with an organocatalyzed aziridination between α,β-unsaturated aldehydes and a protected amine to afford known isolable and stable N-protected aziridine aldehydes. After Boc-deprotection, dimeric species were immediately formed from monomeric N–H aziridine aldehydes. From this building-block new reduced hydantoins were prepared via [3+2]-annulation with isocyanates.
Collapse
Affiliation(s)
- Júlia L. Monteiro
- Centre of Excellence for Research in Sustainable Chemistry , Federal University of São Carlos , São Carlos 13565-905 , SP, Brazil
| | - Natália M. Moreira
- Centre of Excellence for Research in Sustainable Chemistry , Federal University of São Carlos , São Carlos 13565-905 , SP, Brazil
| | - Deborah A. dos Santos
- Centre of Excellence for Research in Sustainable Chemistry , Federal University of São Carlos , São Carlos 13565-905 , SP, Brazil
| | - Márcio W. Paixão
- Centre of Excellence for Research in Sustainable Chemistry , Federal University of São Carlos , São Carlos 13565-905 , SP, Brazil
| | - Arlene G. Corrêa
- Centre of Excellence for Research in Sustainable Chemistry , Federal University of São Carlos , São Carlos 13565-905 , SP, Brazil
| |
Collapse
|
30
|
Konnert L, Lamaty F, Martinez J, Colacino E. Recent Advances in the Synthesis of Hydantoins: The State of the Art of a Valuable Scaffold. Chem Rev 2017. [PMID: 28644621 DOI: 10.1021/acs.chemrev.7b00067] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The review highlights the hydantoin syntheses presented from the point of view of the preparation methods. Novel synthetic routes to various hydantoin structures, the advances brought to the classical methods in the aim of producing more sustainable and environmentally friendly procedures for the preparation of these biomolecules, and a critical comparison of the different synthetic approaches developed in the last twelve years are also described. The review is composed of 95 schemes, 8 figures and 528 references for the last 12 years and includes the description of the hydantoin-based marketed drugs and clinical candidates.
Collapse
Affiliation(s)
- Laure Konnert
- Université de Montpellier, Institut des Biomolécules Max Mousseron UMR 5247 CNRS - Universités Montpellier - ENSCM , Place E. Bataillon, Campus Triolet, cc 1703, 34095 Montpellier, France
| | - Frédéric Lamaty
- Université de Montpellier, Institut des Biomolécules Max Mousseron UMR 5247 CNRS - Universités Montpellier - ENSCM , Place E. Bataillon, Campus Triolet, cc 1703, 34095 Montpellier, France
| | - Jean Martinez
- Université de Montpellier, Institut des Biomolécules Max Mousseron UMR 5247 CNRS - Universités Montpellier - ENSCM , Place E. Bataillon, Campus Triolet, cc 1703, 34095 Montpellier, France
| | - Evelina Colacino
- Université de Montpellier, Institut des Biomolécules Max Mousseron UMR 5247 CNRS - Universités Montpellier - ENSCM , Place E. Bataillon, Campus Triolet, cc 1703, 34095 Montpellier, France
| |
Collapse
|
31
|
Asano M, Hitaka T, Imada T, Yamada M, Morimoto M, Shinohara H, Hara T, Yamaoka M, Santou T, Nakayama M, Imai Y, Habuka N, Yano J, Wilson K, Fujita H, Hasuoka A. Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives. Bioorg Med Chem Lett 2017; 27:1897-1901. [DOI: 10.1016/j.bmcl.2017.03.038] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Revised: 03/14/2017] [Accepted: 03/16/2017] [Indexed: 12/20/2022]
|
32
|
Saravanan K, Elancheran R, Divakar S, Anand SAA, Ramanathan M, Kotoky J, Lokanath N, Kabilan S. Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents. Bioorg Med Chem Lett 2017; 27:1199-1204. [DOI: 10.1016/j.bmcl.2017.01.065] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 01/08/2017] [Accepted: 01/23/2017] [Indexed: 11/28/2022]
|
33
|
Zhou AN, Li B, Ruan L, Wang Y, Duan G, Li J. An improved and practical route for the synthesis of enzalutamide and potential impurities study. CHINESE CHEM LETT 2017. [DOI: 10.1016/j.cclet.2016.09.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Marszałł MP, Sroka WD, Sikora A, Chełminiak D, Ziegler-Borowska M, Siódmiak T, Moaddel R. Ligand fishing using new chitosan based functionalized Androgen Receptor magnetic particles. J Pharm Biomed Anal 2016; 127:129-35. [PMID: 27156644 DOI: 10.1016/j.jpba.2016.04.013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2015] [Revised: 03/17/2016] [Accepted: 04/12/2016] [Indexed: 01/12/2023]
Abstract
Superparamagnetic nanoparticles with chemically modified chitosan has been proposed as a potential support for the immobilization of the androgen receptor (AR). The study involved comparison of different AR carriers like commercially available magnetic beads coated with silica (BcMag) and chitosan coated nanoparticles with different amount of amino groups. The immobilization was carried out through covalent immobilization of the AR through the terminal amino group or through available carboxylic acids. The initial characterization of the AR coated magnetic beads was carried out with dihydrotestosterone, a known AR ligand. Subsequently, chitosan modified nanporticles with long-distanced primary amino groups (Fe3O4CS-(NH2)3) (upto 8.34mM/g) were used for further study to isolate known AR ligands (bicalutamide, flutamide, hydroxyflutamide and levonogestrel) from a mixture of tested compounds in ammonium acetate buffer [10mM, pH 7.4]. The results showed that the selected nanoparticles are a promising semi-quantitative tool for the identification of high affinity compounds to AR and might be of special importance in the identification of novel agonists or antiandrogens.
Collapse
Affiliation(s)
- Michał Piotr Marszałł
- Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Department of Medicinal Chemistry, ul. Jurasza 2, 85-089 Bydgoszcz, Poland.
| | - Wiktor Dariusz Sroka
- Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Department of Medicinal Chemistry, ul. Jurasza 2, 85-089 Bydgoszcz, Poland
| | - Adam Sikora
- Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Department of Medicinal Chemistry, ul. Jurasza 2, 85-089 Bydgoszcz, Poland
| | - Dorota Chełminiak
- Nicolaus Copernicus University in Torun, Faculty of Chemistry Gagarina 7, 87-100 Torun, Poland
| | - Marta Ziegler-Borowska
- Nicolaus Copernicus University in Torun, Faculty of Chemistry Gagarina 7, 87-100 Torun, Poland
| | - Tomasz Siódmiak
- Nicolaus Copernicus University in Torun, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Department of Medicinal Chemistry, ul. Jurasza 2, 85-089 Bydgoszcz, Poland
| | - Ruin Moaddel
- Laboratory of Clinical Investigation, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA
| |
Collapse
|
35
|
Bassetto M, Ferla S, Pertusati F, Kandil S, Westwell AD, Brancale A, McGuigan C. Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. Eur J Med Chem 2016; 118:230-43. [PMID: 27131065 DOI: 10.1016/j.ejmech.2016.04.052] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2015] [Revised: 04/20/2016] [Accepted: 04/21/2016] [Indexed: 11/26/2022]
Abstract
Prostate cancer (PC) is one of the major causes of male death worldwide and the development of new and more potent anti-PC compounds is a constant requirement. Among the current treatments, (R)-bicalutamide and enzalutamide are non-steroidal androgen receptor antagonist drugs approved also in the case of castration-resistant forms. Both these drugs present a moderate antiproliferative activity and their use is limited due to the development of resistant mutants of their biological target. Insertion of fluorinated and perfluorinated groups in biologically active compounds is a current trend in medicinal chemistry, applied to improve their efficacy and stability profiles. As a means to obtain such effects, different modifications with perfluoro groups were rationally designed on the bicalutamide and enzalutamide structures, leading to the synthesis of a series of new antiproliferative compounds. Several new analogues displayed improved in vitro activity towards four different prostate cancer cell lines, while maintaining full AR antagonism and therefore representing promising leads for further development. Furthermore, a series of molecular modelling studies were performed on the AR antagonist conformation, providing useful insights on potential protein-ligand interactions.
Collapse
Affiliation(s)
- Marcella Bassetto
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| | - Salvatore Ferla
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK.
| | - Fabrizio Pertusati
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| | - Sahar Kandil
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| | - Andrew D Westwell
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| | - Andrea Brancale
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| | - Christopher McGuigan
- School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
| |
Collapse
|
36
|
Tomohara K, Ito T, Hasegawa N, Kato A, Adachi I. Direct chemical derivatization of natural plant extract: straightforward synthesis of natural plant-like hydantoin. Tetrahedron Lett 2016. [DOI: 10.1016/j.tetlet.2016.01.054] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
37
|
Lagojda A, Kuehne D, Krug O, Thomas A, Wigger T, Karst U, Schänzer W, Thevis M. Identification of selected in vitro generated phase-I metabolites of the steroidal selective androgen receptor modulator MK-0773 for doping control purposes. EUROPEAN JOURNAL OF MASS SPECTROMETRY (CHICHESTER, ENGLAND) 2016; 22:49-59. [PMID: 27419898 DOI: 10.1255/ejms.1415] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
Research into developing anabolic agents for various therapeutic purposes has been pursued for decades. As the clinical utility of anabolic-androgenic steroids has been found to be limited because of their lack of tissue selectivity and associated off-target effects, alternative drug entities have been designed and are commonly referred to as selective androgen receptor modulators (SARMs). While most of these SARMs are of nonsteroidal structure, the drug candidate MK-0773 comprises a 4-aza-steroidal nucleus. Besides the intended therapeutic use, SARMs have been found to be illicitly distributed and misused as doping agents in sport, necessitating frequently updated doping control analytical assays. As steroidal compounds reportedly undergo considerable metabolic transformations, the phase-I metabolism of MK-0773 was simulated using human liver microsomal (HLM) preparations and electrochemical conversion. Subsequently, major metabolic products were identified and characterized employing liquid chromatography-high-resolution/high- accuracy tandem mass spectrometry with electrospray (ESI) and atmospheric pressure chemical ionization (APCI) as well as nuclear magnetic resonance (NMR) spectroscopy. MK-0773 produced numerous phase-I metabolites under the chosen in vitro incubation reactions, mostly resulting from mono- and bisoxygenation of the steroid. HLM yielded at least 10 monooxygenated species, while electrochemistry-based experiments resulted predominantly in three monohydroxylated metabolites. Elemental composition data and product ion mass spectra were generated for these analytes, ESI/APCI measurements corroborated the formation of at least two N-oxygenated metabolites, and NMR data obtained from electrochemistry-derived products supported structures suggested for three monohydroxylated compounds. Hereby, the hydroxylation of the A-ring located N- bound methyl group was found to be of particular intensity. In the absence of controlled elimination studies, the produced information enables the implementation of new target analytes into routine doping controls and expands the focus of anti-doping efforts concerning this new anabolic agent.
Collapse
Affiliation(s)
- Andreas Lagojda
- Bayer CropScience AG, Alfred-Nobel-Str. 50, 40789 Monheim, Germany.
| | - Dirk Kuehne
- Bayer CropScience AG, Alfred- Nobel-Str. 50, 40789 Monheim, Germany.
| | - Oliver Krug
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany. European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany.
| | - Andreas Thomas
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | - Tina Wigger
- Westfälische Wilhelms-Universität Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48419 Münster, Germany.
| | - Uwe Karst
- Westfälische Wilhelms- Universität Münster, Institute of Inorganic and Analytical Chemistry, Corrensstr. 30, 48419 Münster, Germany.
| | - Wilhelm Schänzer
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany.
| | - Mario Thevis
- Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933 Cologne, Germany. European Monitoring Center for Emerging Doping Agents, Cologne/Bonn, Germany.
| |
Collapse
|
38
|
Rapozzi V, Ragno D, Guerrini A, Ferroni C, della Pietra E, Cesselli D, Castoria G, Di Donato M, Saracino E, Benfenati V, Varchi G. Androgen Receptor Targeted Conjugate for Bimodal Photodynamic Therapy of Prostate Cancer in Vitro. Bioconjug Chem 2015; 26:1662-71. [PMID: 26108715 DOI: 10.1021/acs.bioconjchem.5b00261] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Prostate cancer (PC) represents the most common type of cancer among males and is the second leading cause of cancer death in men in Western society. Current options for PC therapy remain unsatisfactory, since they often produce uncomfortable long-term side effects, such as impotence (70%) and incontinence (5-20%) even in the first stages of the disease. Light-triggered therapies, such as photodynamic therapy, have the potential to provide important advances in the treatment of localized and partially metastasized prostate cancer. We have designed a novel molecular conjugate (DR2) constituted of a photosensitizer (pheophorbide a, Pba), connected to a nonsteroidal anti-androgen molecule through a small pegylated linker. This study aims at investigating whether DR2 represents a valuable approach for PC treatment based on light-induced production of single oxygen and nitric oxide (NO) in vitro. Besides being able to efficiently bind the androgen receptor (AR), the 2-trifluoromethylnitrobenzene ring on the DR2 backbone is able to release cytotoxic NO under the exclusive control of light, thus augmenting the general photodynamic effect. Although DR2 is similarly internalized in cells expressing different levels of androgen receptor, the AR ligand prevents its efflux through the ABCG2-pump. In vitro phototoxicity experiments demonstrated the ability of DR2 to kill cancer cells more efficiently than Pba, while no dark toxicity was observed. Overall, the presented approach is very promising for further development of AR-photosensitizer conjugates in the multimodal photodynamic treatment of prostate cancer.
Collapse
Affiliation(s)
- Valentina Rapozzi
- ‡Department of Medical and Biological Sciences University of Udine, Piazzale Kolbe, 4, 33100 Udine, Italy
| | - Daniele Ragno
- ∥Department of Chemistry University of Ferrara, Via Fossato di Mortara, 17, 44121 Ferrara, Italy
| | - Andrea Guerrini
- †Institute of the Organic Synthesis and Photoreactivity Italian National Research Council, Via P. Gobetti, 101, 40129 Bologna, Italy
| | - Claudia Ferroni
- †Institute of the Organic Synthesis and Photoreactivity Italian National Research Council, Via P. Gobetti, 101, 40129 Bologna, Italy
| | - Emilia della Pietra
- ‡Department of Medical and Biological Sciences University of Udine, Piazzale Kolbe, 4, 33100 Udine, Italy
| | - Daniela Cesselli
- ‡Department of Medical and Biological Sciences University of Udine, Piazzale Kolbe, 4, 33100 Udine, Italy
| | - Gabriella Castoria
- §Department of Biochemistry, Biophysics and General Pathology - II University of Naples , Via L. De Crecchio, 7, 80138 Naples, Italy
| | - Marzia Di Donato
- §Department of Biochemistry, Biophysics and General Pathology - II University of Naples , Via L. De Crecchio, 7, 80138 Naples, Italy
| | - Emanuela Saracino
- ⊥Institute for the Study of Nanostructured Materials, Italian National Research Council, Via P. Gobetti, 101, 40129 Bologna, Italy
| | - Valentina Benfenati
- †Institute of the Organic Synthesis and Photoreactivity Italian National Research Council, Via P. Gobetti, 101, 40129 Bologna, Italy
| | - Greta Varchi
- †Institute of the Organic Synthesis and Photoreactivity Italian National Research Council, Via P. Gobetti, 101, 40129 Bologna, Italy
| |
Collapse
|
39
|
Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Vorobiev AA, Kuznetsova IV, Shevkun NA, Koryakova AG, Karapetian RN, Trifelenkov AS, Kravchenko DV, Veselov MS, Chufarova NV. Design, synthesis and biological evaluation of novel 5-oxo-2-thioxoimidazolidine derivatives as potent androgen receptor antagonists. Eur J Med Chem 2015; 99:51-66. [DOI: 10.1016/j.ejmech.2015.05.039] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2014] [Revised: 05/21/2015] [Accepted: 05/23/2015] [Indexed: 10/23/2022]
|
40
|
Shirakawa S, Yamamoto K, Maruoka K. Phase-Transfer-Catalyzed Asymmetric SNAr Reaction of α-Amino Acid Derivatives with Arene Chromium Complexes. Angew Chem Int Ed Engl 2014. [DOI: 10.1002/ange.201409065] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
41
|
Shirakawa S, Yamamoto K, Maruoka K. Phase-Transfer-Catalyzed Asymmetric SNAr Reaction of α-Amino Acid Derivatives with Arene Chromium Complexes. Angew Chem Int Ed Engl 2014; 54:838-40. [DOI: 10.1002/anie.201409065] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2014] [Indexed: 02/01/2023]
|
42
|
Petit-Topin I, Fay M, Resche-Rigon M, Ulmann A, Gainer E, Rafestin-Oblin ME, Fagart J. Molecular determinants of the recognition of ulipristal acetate by oxo-steroid receptors. J Steroid Biochem Mol Biol 2014; 144 Pt B:427-35. [PMID: 25204619 DOI: 10.1016/j.jsbmb.2014.08.008] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 07/31/2014] [Accepted: 08/07/2014] [Indexed: 11/16/2022]
Abstract
The human progesterone receptor (PR) plays a key role in reproductive function in women. PR antagonists have numerous applications in female health care including regular and emergency contraception, and treatment of hormone-related pathological conditions such as breast cancer, endometriosis, and leiomyoma. The main factor limiting their long-term administration is the fact that they cross-bind to other oxo-steroid receptors. Ulipristal acetate (UPA), a highly potent PR antagonist, has recently come onto the market and is much more selective for PR than the other oxo-steroid receptors (androgen, AR, glucocorticoid, GR, and mineralocorticoid, MR receptors) and, remarkably, it displays lower GR-inactivating potency than RU486. We adopted a structural approach to characterizing the binding of UPA to the oxo-steroid receptors at the molecular level. We solved the X-ray crystal structure of the ligand-binding domain (LBD) of the human PR complexed with UPA and a peptide from the transcriptional corepressor SMRT. We used the X-ray crystal structure of the GR in its antagonist conformation to dock UPA within its ligand-binding cavity. Finally, we generated three-dimensional models of the LBD of androgen and mineralocorticoid receptors (AR and MR) in an antagonist conformation and docked UPA within them. Comparing the structures revealed that the network of stabilizing contacts between the UPA C11 aryl group and the LBD is responsible for its high PR antagonist potency. It also showed that it is the inability of UPA to contact Gln642 in GR that explains why it has lower potency in inactivating GR than RU486. Finally, we found that the binding pockets of AR and MR are too small to accommodate UPA, and allowed us to propose that the extremely low sensitivity of MR to UPA is due to inappropriate interactions with the C11 substituent. All these findings open new avenues for designing new PR antagonist compounds displaying greater selectivity.
Collapse
MESH Headings
- Binding Sites
- Crystallography, X-Ray
- HEK293 Cells
- Hormone Antagonists/pharmacology
- Humans
- Models, Molecular
- Norpregnadienes/pharmacology
- Protein Conformation
- Receptors, Androgen/chemistry
- Receptors, Androgen/metabolism
- Receptors, Mineralocorticoid/chemistry
- Receptors, Mineralocorticoid/metabolism
- Receptors, Progesterone/agonists
- Receptors, Progesterone/antagonists & inhibitors
- Receptors, Progesterone/chemistry
- Receptors, Progesterone/metabolism
Collapse
Affiliation(s)
- I Petit-Topin
- Inserm U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Paris, France; Université Denis Diderot, Site Bichat, Paris, France
| | - M Fay
- Inserm U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Paris, France; Université Denis Diderot, Site Bichat, Paris, France
| | | | - A Ulmann
- Laboratoire HRA Pharma, Paris, France
| | - E Gainer
- Laboratoire HRA Pharma, Paris, France
| | - M-E Rafestin-Oblin
- Inserm U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Paris, France; Université Denis Diderot, Site Bichat, Paris, France
| | - J Fagart
- Inserm U773, Centre de Recherche Biomédicale Bichat-Beaujon CRB3, Paris, France; Université Denis Diderot, Site Bichat, Paris, France; Inserm U693, Le Kremlin - Bicêtre F94276, France; Faculté de Médecine Paris-Sud, Univ Paris-Sud, UMR-S693, Le Kremlin - Bicêtre F94276, France.
| |
Collapse
|
43
|
Blanqué R, Lepescheux L, Auberval M, Minet D, Merciris D, Cottereaux C, Clément-Lacroix P, Delerive P, Namour F. Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization. BMC Musculoskelet Disord 2014; 15:291. [PMID: 25185887 PMCID: PMC4167280 DOI: 10.1186/1471-2474-15-291] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Accepted: 08/27/2014] [Indexed: 11/23/2022] Open
Abstract
Background Muscle wasting is a hallmark of many chronic conditions but also of aging and results in a progressive functional decline leading ultimately to disability. Androgens, such as testosterone were proposed as therapy to counteract muscle atrophy. However, this treatment is associated with potential cardiovascular and prostate cancer risks and therefore not acceptable for long-term treatment. Selective Androgen receptor modulators (SARM) are androgen receptor ligands that induce muscle anabolism while having reduced effects in reproductive tissues. Therefore, they represent an alternative to testosterone therapy. Our objective was to demonstrate the activity of SARM molecule (GLPG0492) on a immobilization muscle atrophy mouse model as compared to testosterone propionate (TP) and to identify putative biomarkers in the plasma compartment that might be related to muscle function and potentially translated into the clinical space. Methods GLPG0492, a non-steroidal SARM, was evaluated and compared to TP in a mouse model of hindlimb immobilization. Results GLPG0492 treatment partially prevents immobilization-induced muscle atrophy with a trend to promote muscle fiber hypertrophy in a dose-dependent manner. Interestingly, GLPG0492 was found as efficacious as TP at reducing muscle loss while sparing reproductive tissues. Furthermore, gene expression studies performed on tibialis samples revealed that both GLPG0492 and TP were slowing down muscle loss by negatively interfering with major signaling pathways controlling muscle mass homeostasis. Finally, metabolomic profiling experiments using 1H-NMR led to the identification of a plasma GLPG0492 signature linked to the modulation of cellular bioenergetic processes. Conclusions Taken together, these results unveil the potential of GLPG0492, a non-steroidal SARM, as treatment for, at least, musculo-skeletal atrophy consecutive to coma, paralysis, or limb immobilization. Electronic supplementary material The online version of this article (doi:10.1186/1471-2474-15-291) contains supplementary material, which is available to authorized users.
Collapse
|
44
|
Chekler ELP, Unwalla R, Khan TA, Tangirala RS, Johnson M, St. Andre M, Anderson JT, Kenney T, Chiparri S, McNally C, Kilbourne E, Thompson C, Nagpal S, Weber G, Schelling S, Owens J, Morris CA, Powell D, Verhoest PR, Gilbert AM. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators. J Med Chem 2014; 57:2462-71. [DOI: 10.1021/jm401625b] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Eugene L. Piatnitski Chekler
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Rayomond Unwalla
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Taukeer A. Khan
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Raghuram S. Tangirala
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Mark Johnson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Michael St. Andre
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - James T. Anderson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Thomas Kenney
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Sue Chiparri
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Chris McNally
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Edward Kilbourne
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Catherine Thompson
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Sunil Nagpal
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Gregory Weber
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Scott Schelling
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Jane Owens
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Carl A. Morris
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Dennis Powell
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Patrick R. Verhoest
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| | - Adam M. Gilbert
- BioTherapeutics Medicinal
Chemistry, Pfizer Global Research and Development, 200 Cambridgepark Drive, Cambridge, Massachusetts 02140, United States
| |
Collapse
|
45
|
Shirakawa S, Yamamoto K, Tokuda T, Maruoka K. Phase-Transfer-Catalyzed Asymmetric α-Arylation of α-Amino Acid Derivatives. ASIAN J ORG CHEM 2014. [DOI: 10.1002/ajoc.201400004] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
46
|
Nagata N, Furuya K, Oguro N, Nishiyama D, Kawai K, Yamamoto N, Ohyabu Y, Satsukawa M, Miyakawa M. Lead evaluation of tetrahydroquinolines as nonsteroidal selective androgen receptor modulators for the treatment of osteoporosis. ChemMedChem 2013; 9:197-206. [PMID: 24273094 DOI: 10.1002/cmdc.201300348] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Revised: 10/24/2013] [Indexed: 11/11/2022]
Abstract
Tetrahydroquinoline (THQ) was deemed to be a suitable scaffold for our nonsteroidal selective androgen receptor modulator (SARM) concept. We adapted the strategy of switching the antagonist function of cyano-group-containing THQ (CN-THQ) to the agonist function and optimized CN-THQ as an orally available drug candidate with suitable pharmacological and ADME profiles. Based on binding mode analyses and synthetic accessibility, we designed and synthesized a compound that possesses a para-substituted aromatic ring attached through an amide linker. The long-tail THQ derivative 6-acetamido-N-(2-(8-cyano-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-4-yl)-2-methylpropyl)nicotinamide (1 d), which bears a para-acetamide-substituted aromatic group, showed an appropriate in vitro biological profile, as expected. We considered that the large conformational change at Trp741 of the androgen receptor (AR) and the hydrogen bond between 1 d and helix 12 of the AR could maintain the structure of the AR in its agonist form; indeed, 1 d displays strong AR agonistic activity. Furthermore, 1 d showed an appropriate in vivo profile for use as an orally available SARM, displaying clear tissue selectivity, with a separation between its desirable osteoanabolic effect on femoral bone mineral density and its undesirable virilizing effects on the uterus and clitoral gland in a female osteoporosis model.
Collapse
Affiliation(s)
- Naoya Nagata
- Central Research Laboratories, Kaken Pharmaceutical Co. Ltd. 14 Shinomiya, Minamikawara-cho, Yamashina, Kyoto 607-8042 (Japan).
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Thevis M, Piper T, Beuck S, Geyer H, Schänzer W. Expanding sports drug testing assays: mass spectrometric characterization of the selective androgen receptor modulator drug candidates RAD140 and ACP-105. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2013; 27:1173-1182. [PMID: 23650030 DOI: 10.1002/rcm.6558] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/22/2013] [Accepted: 02/26/2013] [Indexed: 06/02/2023]
Abstract
RATIONALE Anabolic agents have been top-ranked for many years among statistics of adverse analytical findings compiled by the World Anti-Doping Agency (WADA). Besides archetypical anabolic-androgenic steroids (AAS), alternative substances with similar effects concerning bone and muscle anabolism have been therapeutically pursued. A prominent emerging class of drugs is the chemically heterogeneous group of selective androgen receptor modulators (SARMs), some of which have been detected in doping control samples between 2009 and 2012 despite missing clinical approval. METHODS In order to support the momentum of expanding the preventive and proactive measures among anti-doping laboratories, the analytical characterization of substances with misuse potential is of great importance. In the present study, the SARM drug candidates RAD140 (comprising a 5-phenyloxadiazole nucleus) and ACP-105 (bearing an N-substituted tropanol pharmacophore) were studied regarding their mass spectrometric behavior under ESI-MS(/MS) and EI-MS(/MS) conditions. Reference material was synthesized according to established protocols and dissociation pathways of RAD140 and ACP-105 were elucidated with liquid chromatography/electrospray ionization quadrupole/time-of-flight or iontrap/orbitrap and gas chromatography/electron ionization quadrupole/time-of-flight high resolution/high accuracy mass spectrometry. RESULTS Fragmentation pathways to diagnostic product ions of RAD140 (e.g. m/z 223 and 205 using ESI-MS/MS and m/z 421 and 349 using EI-MS/MS) and ACP-105 (such as m/z 233 and 193 or 231 and 217 for ESI-MS/MS and EI-MS/MS measurements, respectively) were proposed as substantiated by determined elemental compositions and MS(n) experiments as well as comparison to spectra of a structural analog. Notably, for the formation of the characteristic fragment ion at m/z 421 of RAD140, the comparably seldom intramolecular migration of a trimethylsilyl residue triggered by electron ionization was suggested as corroborated by all of the above-mentioned analytical means. CONCLUSIONS The obtained data will support future sports drug testing methods and facilitate and accelerate the implementation of this analyte and related compounds or metabolites in both GC/MS(/MS)- and LC/MS(/MS)-based routine doping control procedures.
Collapse
Affiliation(s)
- Mario Thevis
- Institute of Biochemistry-Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany.
| | | | | | | | | |
Collapse
|
48
|
Lallous N, Dalal K, Cherkasov A, Rennie PS. Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer. Int J Mol Sci 2013; 14:12496-519. [PMID: 23771019 PMCID: PMC3709796 DOI: 10.3390/ijms140612496] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 05/29/2013] [Accepted: 06/03/2013] [Indexed: 01/22/2023] Open
Abstract
Recurrent, metastatic prostate cancer continues to be a leading cause of cancer-death in men. The androgen receptor (AR) is a modular, ligand-inducible transcription factor that regulates the expression of genes that can drive the progression of this disease, and as a consequence, this receptor is a key therapeutic target for controlling prostate cancer. The current drugs designed to directly inhibit the AR are called anti-androgens, and all act by competing with androgens for binding to the androgen/ligand binding site. Unfortunately, with the inevitable progression of the cancer to castration resistance, many of these drugs become ineffective. However, there are numerous other regulatory sites on this protein that have not been exploited therapeutically. The regulation of AR activity involves a cascade of complex interactions with numerous chaperones, co-factors and co-regulatory proteins, leading ultimately to direct binding of AR dimers to specific DNA androgen response elements within the promoter and enhancers of androgen-regulated genes. As part of the family of nuclear receptors, the AR is organized into modular structural and functional domains with specialized roles in facilitating their inter-molecular interactions. These regions of the AR present attractive, yet largely unexploited, drug target sites for reducing or eliminating androgen signaling in prostate cancers. The design of small molecule inhibitors targeting these specific AR domains is only now being realized and is the culmination of decades of work, including crystallographic and biochemistry approaches to map the shape and accessibility of the AR surfaces and cavities. Here, we review the structure of the AR protein and describe recent advancements in inhibiting its activity with small molecules specifically designed to target areas distinct from the receptor’s androgen binding site. It is anticipated that these new classes of anti-AR drugs will provide an additional arsenal to treat castration-resistant prostate cancer.
Collapse
Affiliation(s)
- Nada Lallous
- Vancouver Prostate Centre, University of British Columbia, 2660 Oak Street, Vancouver, BC V6H 3Z6, Canada.
| | | | | | | |
Collapse
|
49
|
Chai W, Nguyen E, Doran J, Han K, Weatherbie A, Fernandez D, Karimi S, Mynam R, Humphrey C, Rana S, Buynak JD. Urazole synthesis. Part 2: facilitating N4 substitution. Tetrahedron Lett 2013. [DOI: 10.1016/j.tetlet.2013.02.042] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
50
|
Zhu K, Huang H, Wu W, Wei Y, Ye J. Aminocatalyzed asymmetric Diels–Alder reaction of 2,4-dienals and rhodanine/hydantoin derivatives. Chem Commun (Camb) 2013; 49:2157-9. [DOI: 10.1039/c3cc00023k] [Citation(s) in RCA: 46] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|